Idris Abiodun Olasupo

Dr. Idris Abiodun Olasupo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Acta Crystallographica Section C Structural Chemistry
Verified
Journal Article
Open access
PDF file
SKSherif O. Kolade
Sherif O. Kolade
Josephat U. IzunobiJosephat U. Izunobi
Josephat U. Izunobi
AGAllen T. Gordon
Allen T. Gordon
EHEric Cyriel Hosten
Eric Cyriel Hosten
IOIdris Abiodun Olasupo
Idris Abiodun Olasupo
OFOluwole Familoni
Oluwole Familoni
In the search for new `sulfa drugs' with therapeutic properties, o-nitrosulfonamides and N-cycloamino-o-sulfanilamides were synthesized and characterized using techniques including 1H NMR, 13C NMR and FT–IR spectroscopy, and single-crystal X-ray diffraction (SC-XRD). The calculated density functional theory (DFT)-optimized geometry of the molecules showed similar conformations to those obtained by SC-XRD. Molecular docking of N-piperidinyl-o-sulfanilamide and N-indolinyl-o-sulfanilamide supports the notion that o-sulfanilamides are able to bind to human carbonic anhydrase II and IX inhibitors (hCA II and IX; PDB entries 4iwz and 5fl4). Hirshfeld surface analyses and DFT studies of three o-nitrosulfonamides {1-[(2-nitrophenyl)sulfonyl]pyrrolidine, C10H12N2O4S, 1, 1-[(2-nitrophenyl)sulfonyl]piperidine, C11H14N2O4S, 2, and 1-[(2-nitrophenyl)sulfonyl]-2,3-dihydro-1H-indole, C14H12N2O4S, 3} and three N-cycloamino-o-sulfanilamides [2-(pyrrolidine-1-sulfonyl)aniline, C10H14N2O2S, 4, 2-(piperidine-1-sulfonyl)aniline, C11H16N2O2S, 5, and 2-(2,3-dihydro-1H-indole-1-sulfonyl)aniline, C14H14N2O2S, 6] suggested that forces such as hydrogen bonding and π–π interactions hold molecules together and further showed that charge transfer could promote bioactivity and the ability to form biological interactions at the piperidinyl and phenyl moieties.

8 December 2023 in Journal of Cluster Science
Verified
Journal Article
Closed access
PDF file
KOKafayat A Owoseni-Fagbenro
Kafayat A Owoseni-Fagbenro
SSSalim Saifullah
Salim Saifullah
MIMuhammad Imran
Muhammad Imran
SPSamina Perveen
Samina Perveen
MKMuhammad Kawish
Muhammad Kawish
LALuqman A. Adams
Luqman A. Adams

24 July 2020 in Acta Crystallographica Section C Structural Chemistry
Verified
Journal Article
Closed access
PDF file
SKSherif O. Kolade
Sherif O. Kolade
JIJosephat Izunobi
Josephat Izunobi
EHEric Cyriel Hosten
Eric Cyriel Hosten
IOIdris Abiodun Olasupo
Idris Abiodun Olasupo
Adeniyi OgunlajaAdeniyi Ogunlaja
Adeniyi Ogunlaja
OFOluwole B. Familoni
Oluwole B. Familoni

14 October 2025 in Innovative Medicines & Omics
Verified
Journal Article
Open access
PDF file
OAOluwafemi Segun AINA
Oluwafemi Segun AINA
OEOwoyemi Wahab Elegbeleye
Owoyemi Wahab Elegbeleye
NBNafisat O. Babamusa
Nafisat O. Babamusa
MRMujeeb O. Rofiu
Mujeeb O. Rofiu
KOKafayat A Owoseni-Fagbenro
Kafayat A Owoseni-Fagbenro
OFOluwole Familoni
Oluwole Familoni
Alzheimer’s disease (AD), one of the neurodegenerative disorders, is marked by the gradual degeneration of nerve cells in the brain or peripheral nervous system, along with abnormal protein aggregation. While significant efforts have been made to manage AD, a dearth of data remains on candidate phytochemicals and analogs in its treatment. Herein, we present alkaloids derived from the marine algae Jania rubens as potential inhibitors of human acetylcholinesterase (AChE) relevant to AD therapy. Using in silico tools, such as Protox II and SwissADME, 40 isolates were screened for toxicity and absorption, distribution, metabolism, and excretion properties. Molecular docking simulations were performed using PyRx 0.8, AutoDock Vina Wizard, and Discovery Studio 2020. A 50-nanosecond molecular dynamics simulation was performed using the Groningen Molecular Simulation in the LINUX environment and bio-organic molecules force field simulation (CHARMM 36). Ursodeoxycholic acid (AL20), an isolate from J. rubens, exhibited strong inhibitory activity against AChE with a binding energy of −8.5 kcal/mol, surpassing standard anti-Alzheimer drugs donepezil (−8.3 kcal/mol), galantamine (−7.7 kcal/mol), and rivastigmine (−6.4 kcal/mol). However, in silico data revealed a 73% probability of hepatotoxicity for AL20. Thereafter, seven derivatives (AL20A–G) were designed to improve properties for drug likeness. The amide analog, AL20E, showed superior inhibitory activity (−9.0 kcal/mol) and non-toxicity compared to AL20 and the standard drugs. This derivative also demonstrated strong interactions with the AChE enzyme, forming three hydrogen bonds with amino acid residues Pro290, Ser293, and Leu289. The brain or intestinal estimated permeation model predicted favorable gastrointestinal absorption and blood–brain barrier penetration for AL20E, indicating its potential as a central nervous system-active drug. Density functional theory and molecular dynamics analyses confirmed the chemical stability of AL20E, making it a promising candidate for the development of an anti-Alzheimer drug. This study highlights AL20E ([4R]-4-[{3S,7S,8R,9S,10S,13R,14S,17R}-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H cyclopenta{a}phenanthren-17-yl]pentanamide) as a non-toxic, AchE inhibitor with enhanced drug-likeness. This study thereby presents AL20E for consideration as a lead compound in the development of novel Alzheimer’s therapeutics.